Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 501

Sort by

Sort Order Select

Journal Articles

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Matthew C. Foster, Barbara Savoldo, Winnie Lau, Clio Rubinos, Natalie Grover, Paul Armistead, James Coghill, Robert S. Hagan, Kaitlin Morrison, Faith Brianne Buchanan, Catherine Cheng, Spencer Laing, Anastasia Ivanova, John West, Aaron Foster, Jonathan Serody, Gianpietro Dotti

Blood (2021) 137 (23): 3306–3309.

https://doi.org/10.1182/blood.2021010784

Published: 2021

Includes: Supplemental data

Journal Articles

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Rebecca A. Gardner, Francesco Ceppi, Julie Rivers, Colleen Annesley, Corinne Summers, Agne Taraseviciute, Juliane Gust, Kasey J. Leger, Katherine Tarlock, Todd M. Cooper, Olivia C. Finney, Hannah Brakke, Daniel H. Li, Julie R. Park, Michael C. Jensen

Blood (2019) 134 (24): 2149–2158.

https://doi.org/10.1182/blood.2019001463

Published: 2019

Includes: Supplemental data

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

David A Sallman, MD, Jason B. Brayer, PhDMD, Xavier Poire, Violaine Havelange, Ahmad Awada, MD PhD, Philippe Lewalle, Kunle Odunsi, MD, Eunice S. Wang, MD, Caroline Lonez, PhD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Nathalie Braun, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3826.

https://doi.org/10.1182/blood-2019-128020

Published: 2019

Journal Articles

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Erica Brivio, MD, Raoull Hoogendijk, MSc, Christophe Chantrain, MD PhD, Fanny Rialland, MD, Audrey Contet, Sarah Elitzur, MD, Luciano Dalla-Pozza, MBBS FRACP, Krisztian Kallay, MD, Chi Kong Li, MBBS,MD, Motohiro Kato, MD PhD, Inna V Markova, Dr., Kjeld Schmiegelow, Professor MD DMSc., Nicole Bodmer, Rob Pieters, MDPhDMSc, Christian Michel Zwaan, MD PhD

Blood (2019) 134 (Supplement_1): 3890.

https://doi.org/10.1182/blood-2019-126472

Published: 2019

Journal Articles

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Blood (2019) 134 (Supplement_1): 5343.

https://doi.org/10.1182/blood-2019-126594

Published: 2019

Journal Articles

Targeting the FMS-like Tyrosin Kinase 3 with the Unicar System: Preclinical Comparison of Murine and Humanized Single-Chain Variable Fragment-Based Targeting Modules

Frederick Fasslrinner, MD, Claudia Arndt, PhD, Anja Feldmann, PhD, Stefanie Koristka, PhD, Liliana Raquel Loureiro, PhD, Marc Schmitz, MD, Gundram Jung, MD, Martin Bornhaeuser, MD, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5614.

https://doi.org/10.1182/blood-2019-124279

Published: 2019

Journal Articles

Clinical Presentation, Management and Biomarkers of Cytokine Release Syndrome after Anti-CD19 CART-Cell Therapy for r/r ALL

Ping Li, Lili Zhou, Shiguang Ye, Shaoguang Li, Aibin Liang, MD PhD

Blood (2019) 134 (Supplement_1): 5625.

https://doi.org/10.1182/blood-2019-130119

Published: 2019

Journal Articles

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Sepideh Mokhtari, MD, Justin M Asquith, MD, Christina A Bachmeier, PharmD, Michael D. Jain, MD PhD, Peter Forsyth, MD, Frederick L. Locke, MD, Youngchul Kim, PhD, Aleksandr Lazaryan, MD PhD MPH

Blood (2019) 134 (Supplement_1): 5627.

https://doi.org/10.1182/blood-2019-122343

Published: 2019

Journal Articles

Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes

Mazyar Shadman, MD, Jordan Gauthier, MD MSc, Sirin Khajavian, MD, Alexandre V. Hirayama, MD, Ryan C. Lynch, MD, Stephen D. Smith, MD, Chaitra S. Ujjani, MD, Victor A. Chow, MD, Hans-Peter Kiem, MD PhD, Brian G. Till, MD, Ajay K. Gopal, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 4294.

https://doi.org/10.1182/blood-2019-126269

Published: 2019

Journal Articles

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

Blood (2019) 134 (Supplement_1): 2619.

https://doi.org/10.1182/blood-2019-129279

Published: 2019

Journal Articles

shRNA-Interleukin-6 Modified CD19-Specific Chimeric Antigen Receptor T Cell Significantly Improves the Safety in Acute Lymphoblastic Leukemia

Liqing Kang, Xiaowen Tang, Nan Xu, Minghao Li, Jingwen Tan, Wei Qi, Zhou Yu, Xiaoyan Lou, Shengli Xue, Xin Li, MD, Jian Zhang, MD, Jia Chen, MD, Zhenkun Wang, PhD, Caixia Li, Fu Cheng Cheng, MD PhD, Depei Wu, MD PhD, Lei Yu, MD PhD

Blood (2019) 134 (Supplement_1): 2621.

https://doi.org/10.1182/blood-2019-132067

Published: 2019

Journal Articles

Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 2622.

https://doi.org/10.1182/blood-2019-125342

Published: 2019

Journal Articles

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Blood (2019) 134 (Supplement_1): 2625.

https://doi.org/10.1182/blood-2019-130370

Published: 2019

Journal Articles

Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

Persis J Amrolia, FRCP, FRCPath, PhD, Robert Wynn, MD, Rachael E Hough, MD, Ajay Vora, Denise Bonney, Paul Veys, MD PhD, Robert Chiesa, Kanchan Rao, Liz Clark, Muhammad Al-Hajj, Shaun P Cordoba, PhD, Shimobi Onuoha, PhD, Ekaterini Kotsopoulou, Nushmia Z Khokhar, Martin Pule, MD, Vijay G R Peddareddigari

Blood (2019) 134 (Supplement_1): 2620.

https://doi.org/10.1182/blood-2019-123424

Published: 2019

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt

Blood (2019) 134 (Supplement_1): 2871.

https://doi.org/10.1182/blood-2019-123978

Published: 2019

Journal Articles

Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029

Zhitao Ying, MD PhD, Pengpeng Xu, MD, Li Wang, MD PhD, Shu Cheng, MD PhD, Wen Wu, MD PhD, Wen Wang, MD PhD, Ming Hao, PhD, Su Yang, Harry Lam, PhD, James Li, Hongxia Zheng, MD PhD, Weili Zhao, MD PhD, Yuqin Song, MD PhD, Jun Zhu, BS

Blood (2019) 134 (Supplement_1): 2876.

https://doi.org/10.1182/blood-2019-127751

Published: 2019

Journal Articles

Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts

Michelle J. Cox, Charles J. Kuhlmann, Rosalie M. Sterner, Reona Sakemura, MD PhD, Sutapa Sinha, PhD, Raphael Mwangi, MS, Nancy Scott, MS, Mehrdad Hefazi, MD, Omar Ahmed, Dale Chappell, Cameron Durrant, Claudia Manriquez Roman, Kendall J. Schick, Erin E. Tapper, Paulina Horvei, MD, Michael W. Ruff, MD, Sameer A. Parikh, MD, Neil E. Kay, MD, Saad S. Kenderian, MD

Blood (2019) 134 (Supplement_1): 3868.

https://doi.org/10.1182/blood-2019-129349

Published: 2019

Journal Articles

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Colleen Annesley, MD, Corinne Summers, MD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie Rivers, MD, Adam J. Lamble, MD, Ashley Wilson, PhD, Qian Vicky Wu, PhD, Adam Brand, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2019) 134 (Supplement_1): 3869.

https://doi.org/10.1182/blood-2019-131447

Published: 2019

Journal Articles

Granulocyte Colony-Stimulating Factor (G-CSF) Interactions with Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma

Daria Gaut, MD, Kevin Tang, BS, BA, Myung Sim, PhD, Tuyen Duong, Joshua Sasine, MD PhD, Patricia A. Young, MD

Blood (2019) 134 (Supplement_1): 4109.

https://doi.org/10.1182/blood-2019-122195

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Targeting the FMS-like Tyrosin Kinase 3 with the Unicar System: Preclinical Comparison of Murine and Humanized Single-Chain Variable Fragment-Based Targeting Modules

Clinical Presentation, Management and Biomarkers of Cytokine Release Syndrome after Anti-CD19 CART-Cell Therapy for r/r ALL

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

shRNA-Interleukin-6 Modified CD19-Specific Chimeric Antigen Receptor T Cell Significantly Improves the Safety in Acute Lymphoblastic Leukemia

Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029

Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Granulocyte Colony-Stimulating Factor (G-CSF) Interactions with Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only